Drug · CHEMBL484
ADEFOVIR
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. ADEFOVIR. Drugs and targets, record CHEMBL484. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL484
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases4
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| hepatitis B virus infection | Phase 3 | ClinicalTrials.gov | 16 | 15 | https://conductscience.org/library/drugs?q=MONDO_0005344 |
| chronic hepatitis B virus infection | Phase 3 | ClinicalTrials.gov | 10 | 10 | https://conductscience.org/library/drugs?q=MONDO_0005366 |
| HIV infectious disease | Phase 1 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0005109 |
| hepatocellular carcinoma | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0007256 |
Source Open Targets
Trials49
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more that Open Targets linked to it is not shown, since the release's checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00410202 | Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus | Phase 3 | 629 | 2012-07-04 | adefovir | Its name | ClinicalTrials.gov |
| NCT00922207 | A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Adefovir or Entecavir in Patients With HBeAg-Positive Chronic Hepatitis B | Phase 4 | 280 | 2015-11-20 | adefovir | Its name | ClinicalTrials.gov |
| NCT00718887 | Suboptimal Responders to Adefovir Switching to Entecavir | Phase 4 | 228 | 2013-02-11 | adefovir | Its name | ClinicalTrials.gov |
| NCT00065507 | Comparison of Entecavir to Adefovir in Chronic Hepatitis B Virus (HBV) Patients With Hepatic Decompensation | Phase 3 | 195 | 2010-07-02 | adefovir | Its name | ClinicalTrials.gov |
| NCT01023217 | Entecavir Plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B Patients Who Fail Lamivudine Plus Adefovir | Phase 4 | 90 | 2014-01-13 | adefovir | Its name | ClinicalTrials.gov |
| NCT00096785 | Comparative Trial of Entecavir Versus Adefovir in the Treatment of Chronic Hepatitis B Infection | Phase 3 | 69 | 2010-01-06 | adefovir | Its name | ClinicalTrials.gov |
| NCT00371761 | PegIntron Versus Adefovir in the Treatment of Chronic Hepatitis B (CHB) e Antigen Positive Patients in Taiwan (P04498/MK-4031-278) | Phase 3 | 25 | 2010-12-15 | adefovir | Its name | ClinicalTrials.gov |
| NCT02327663 | Emtricitabine for Naive Chinese Chronic Hepatitis B Patients | Phase 4 | 2,000 | adefovir | Its name | ClinicalTrials.gov | |
| NCT01834508 | 3E Extension Study | Phase 4 | 600 | adefovir | Its name | ClinicalTrials.gov | |
| NCT02366247 | Phase Ⅲ Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg-positive Chronic Hepatitis B | Phase 3 | 463 | adefovir | Its name | ClinicalTrials.gov |
1 to 10 of 49
See all 49 trialsComparisons in its trials11
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Entecavir (ETV) 1.0 mg vs Adefovir (ADV) 10 mg: Number of Participants With HBV DNA < 300 Copies/mL by PCR At Week 48 | 57 of 100 | 18 of 91 | 191 | NCT00065507 | Trial comparisons |
| Entecavir (ETV) 1.0 mg vs Adefovir (ADV) 10 mg: Number of Participants With HBV DNA < 300 Copies/mL by PCR At Week 24 | 49 of 100 | 15 of 91 | 191 | NCT00065507 | Trial comparisons |
| ADEFOVIR vs ENTECAVIR: serious adverse events | 59 of 89 | 70 of 102 | 191 | NCT00065507 | Trial comparisons |
| Entecavir, 0.5 mg QD vs Adefovir, 10 mg QD/Entecavir, 0.5 mg QD: serious adverse events | 1 of 89 | 0 of 77 | 166 | NCT00718887 | Trial comparisons |
| Adefovir Plus Entecavir vs Adefovir Plus Lamivudine: Complete Virologic Response (CVR, Serum HBV DNA Undetectable by PCR or Less Than 60 IU/mL) | 13 of 45 | 2 of 45 | 90 | NCT01023217 | Trial comparisons |
| Adefovir Plus Entecavir vs Adefovir Plus Lamivudine: serious adverse events | 2 of 45 | 2 of 45 | 90 | NCT01023217 | Trial comparisons |
| ADV 10 mg vs ETV 0.5 mg: serious adverse events | 2 of 33 | 1 of 36 | 69 | NCT00096785 | Trial comparisons |
| Entecavir vs Adefovir: Alanine Aminotransferase (ALT) Normalization | 25 of 33 | 20 of 32 | 65 | NCT00096785 | Trial comparisons |
| Entecavir vs Adefovir: Viral Load Undetectable (HBV DNA <300 Copies/mL) | 19 of 33 | 6 of 32 | 65 | NCT00096785 | Trial comparisons |
| PegIntron vs Adefovir: Number of Participants With a Combined Response Consisting of All Three Responses - (a) Serological Response, (b) Virological Response, and (c) Biochemical Response | 0 of 13 | 0 of 12 | 25 | NCT00371761 | Trial comparisons |
1 to 10 of 11
See all 11 comparisons in its trialsPapers from its trials16
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL484
GET https://conductscience.org/api/drugs/v1/CHEMBL484/trials?page=2